INTERIM FORMULARY UPDATE

The following recommendations, made at the April 29, 2016 meeting of the Executive Formulary Committee, are approved:

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on New Drug Applications:

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Dosage Form</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levalbuterol</td>
<td>Xopenex, ®</td>
<td>Aerosol, inhalation, HFA: 45 mcg/dose Nebulization Solution, inhalation: 0.31 mg/3 mL, 0.63 mg/3 mL, 1.25 mg/3 mL</td>
<td>Beta 2 Agonist; Short Acting</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>Prozac®</td>
<td>Capsule: 40 mg</td>
<td>Antidepressants; Serotonin Selective Reuptake Inhibitors (SSRIs)</td>
</tr>
<tr>
<td>Insulin lispro and insulin lispro protamine</td>
<td>HumaLOG® Mix 50/50</td>
<td>Injection: 100 units/ml</td>
<td>Antidiabetic Agents, Insulins, Human</td>
</tr>
<tr>
<td>hydrocodone/acetaminophen</td>
<td></td>
<td>Tablet: 7.5/325 mg</td>
<td>Analgesics; Miscellaneous Analgesics &amp; Antipyretics</td>
</tr>
<tr>
<td>Ketoconazole shampoo</td>
<td>Nizoral®</td>
<td>Shampoo: 1%</td>
<td>Dermatologicals; Antifungals</td>
</tr>
<tr>
<td>Pramoxine Foam</td>
<td>Proctofoam®</td>
<td>Foam: 1%</td>
<td>Rectal Agents</td>
</tr>
<tr>
<td>Triamcinolone Paste</td>
<td></td>
<td>Paste, dental: 0.1%</td>
<td>Mouth &amp; Throat Agents</td>
</tr>
<tr>
<td>Ciclopirox cream</td>
<td>Loprox®</td>
<td>0.77%</td>
<td>Dermatologicals; Antifungals</td>
</tr>
</tbody>
</table>

Product(s) **deleted** from the DADS/DSHS Drug Formulary:

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Dosage forms to be deleted</th>
<th>Dosage forms still available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphenhydramine</td>
<td>Benadryl®</td>
<td>50mg, Tablet</td>
<td>Capsule: 25mg, 50mg</td>
</tr>
<tr>
<td>Meclizine</td>
<td>Antivert®</td>
<td>50mg, Tablet</td>
<td>Tablet: 12.5mg, 25mg</td>
</tr>
<tr>
<td>Prochlorperazine</td>
<td>Compazine®</td>
<td>25mg, Tablet</td>
<td>Injection: 5mg/ml Suppository Rectal: 25mg Tablet: 12.5mg, 50mg</td>
</tr>
<tr>
<td>Trimethobenzamide</td>
<td>Tigan</td>
<td>250mg, Capsule 200mg, Suppository (Rectal)</td>
<td>Injection: 100mg/ml</td>
</tr>
</tbody>
</table>

Other **Recommendation(s)/addition(s)/revisions(s)** to the tables listed in the DADS/DSHS Drug Formulary Dosage changes to be made Psychotropic tables:

**Antipsychotics**
- Aripiprazole
  - Child: Add ages 4-11; (Lit)
- Asenapine
  - Child: Change ID to ages 10 to < 12; 20 mg; (Lit)
  - Adolescent: Change ID to 20 mg
- Brexpiprazole
  - Child: Add ID
  - Adolescent: Add ID
- Cariprazine
  - Child: Shade box
  - Adolescent: Shade box
- Clozapine
  - Child: Add ages 8-11
- Haloperidol
  - Child: Change listing to – ages 3-12; Lesser of 0.15 mg/kg or 6 mg; (Lit)
  - Adolescent: Change listing to – ages > 12; acute agitation 10 mg; psychosis 15 mg; Tourette 15 mg; (Lit)
- Olanzapine
  - Child: Change listing to – Ages 4-6; 12.5 mg; Ages 6-12; 20 mg; (Lit)
  - Adolescent: Add ages 13-17; Delete (Lit)
- Paliperidone
  - Adolescent: Delete (Lit)
- Perphenazine
  - Adolescent: Add ages >12
- Quetiapine
  - Child: Change (≤ 9 y/o) to (5-9 y/o)
  - Adolescent: Delete (Lit)
- Risperidone
  - Child: Change listing to – 5 to < 12; 3 mg; Delete (Lit)
- Ziprasidone
  - Child: Change listing to – 10-11; 803 (≤ 45 kg); 1603 (> 45 kg); 404; (Lit)

Antidepressants
- Bupropion (immediate release)
  - Child: Add ages 6 to < 12)
- Citalopram
  - Child: Add ages 6 to < 12)
- Clomipramine
  - Child: Change listing to – 10-11; Lesser of 3 mg/kg or 200 mg (OCD)
  - Adolescent: Change listing to – Lesser of 3 mg/kg or 200 mg (OCD)
- Duloxetine
  - Child: Change listing to -  7 – 12; 120; (Lit)
  - Adolescent: Change listing of 60 to 120
- Escitalopram
  - Child: Add ages 6-11
  - Adolescent: Add ages ≥ 12
- Fluoxetine
  - Child: Add ages 6 to < 12
- Fluvoxamine
  - Child: Add ages 8-11; (OCD)
  - Adolescent: Add ages 12-17 (OCD)
- Imipramine
  - Child: Add ages 6 to < 12
- Mirtazapine
  - Child: Change listing to – 3 to < 12; 45 mg (Lit)
  - Adolescent: Change listing to – 45 mg (Lit)
- Nortriptyline
  - Child: Add ages ≥ 6
- Sertraline
  - Child: Delete (Lit)
- Venlafaxine
  - Child: Add ages 7-11
  - Adolescent: Add ages ≥ 12

Mood Stabilizers
- Carbamazepine
  - Child: Change listing to - < 6; 35 mg/kg; 6 to < 12; 1,000 mg (6-12 mcg/ml)
- Lamotrigine
• Child: add ages 6 to < 12

Lithium
• Therapeutic Serum Concentration: Change Child and Adol listings to – Child & Adol – Max 1.2 mEq/L: (Lit)
  o Child: Change listing to - ≥ 6; #; 1800 mg or (1.2 mEq/L); (Lit)
  o Adolescent: Change listing to - #; 1800 mg or (1.2 mEq/L); (Lit)

Oxcarbazepine
• Child: Add ages 7-12

Valproic acid, valproate, divalproex
• Child: Change listing to – ≥ 6; #; 1800 mg or (1.2 mEq/L); (Lit)
  o Adolescent: Change listing to - #; 1800 mg or (1.2 mEq/L); (Lit)

• Lithium
  o Therapeutic Serum Concentration: Change Child and Adol listings to – Child & Adol – Max 1.2 mEq/L: (Lit)
  o Child: Change listing to - ≥ 6; #; 1800 mg or (1.2 mEq/L); (Lit)
  o Adolescent: Change listing to - #; 1800 mg or (1.2 mEq/L); (Lit)

• Oxcarbazepine
  o Child: Add ages 7-12

Miscellaneous Drugs Used for Psychotropic Purposes
• Atomoxetine
  o Child: Change listing to - ≥ 6; whichever is less; 1.8 mg/kg or 100 mg; (Lit)
  o Adolescent: Change listing to - whichever is less; 1.8 mg/kg or 100 mg; (Lit)

Stimulants
• Amphetamine Mixture
  o Child: for immediate release add ages ≥3; for XR add ages ≥ 6

Dextroamphetamine
• Child: Change listing to – 3-5; 30 mg; ≥ 6; > 50 kg; 60 mg; (Lit)
  o Adolescent: Change listing to - > 50 kg; 60 mg; (Lit)

Methylphenidate
• Child: Add ages ≥ 6 to the immediate release; for Concerta® add ages 6-12

• Amphetamine Mixture
  o Child: for immediate release add ages ≥3; for XR add ages ≥ 6

Dextroamphetamine
• Child: Change listing to – 3-5; 30 mg; ≥ 6; > 50 kg; 60 mg; (Lit)
  o Adolescent: Change listing to - > 50 kg; 60 mg; (Lit)

Methylphenidate
• Child: Add ages ≥ 6 to the immediate release; for Concerta® add ages 6-12

• Amphetamine Mixture
  o Child: for immediate release add ages ≥3; for XR add ages ≥ 6

Dextroamphetamine
• Child: Change listing to – 3-5; 30 mg; ≥ 6; > 50 kg; 60 mg; (Lit)
  o Adolescent: Change listing to - > 50 kg; 60 mg; (Lit)

Methylphenidate
• Child: Add ages ≥ 6 to the immediate release; for Concerta® add ages 6-12

Miscellaneous Drugs Used for Psychotropic Purposes
• Atomoxetine
  o Child: Change listing to - ≥ 6; whichever is less; 1.8 mg/kg or 100 mg; (Lit)
  o Adolescent: Change listing to - whichever is less; 1.8 mg/kg or 100 mg; (Lit)

Clonidine immediate release
• Child: Add ages ≥ 6

Clonidine extended release
• Child: Add ages ≥ 6

Guanfacine immediate release
• Child: Add ages ≥ 6

Guanfacine extended release
• Child: Add ages 6-12
  o Adolescent: Change listing to ≥ 13; 7 mg

Hypnotics
• Diphenhydramine
  o Add the following note to listing: “Evidence suggests that tolerance develops to the hypnotic effects within 5-7 nights of continuous use”

• Hydroxyzine

Bronchodilators
• Albuterol
  o Add – Powder, inhalation: ProAir Respiclick® 117 mcg/actuation
  o Delete trade name Vospire ER®
  o Delete size: 17 gm
  o Change “chlorofluorocarbon free” to “HFA”
  o Change “Solution, inhalation” to “Nebulization Solution, inhalation”

Aminophylline
• Delete all aminophylline products as the rectal suppository and oral tablet have been discontinued and it is unlikely that the injection would be used

Ipratropium
• Delete “Inhaler” from trade name
  o Change “18 mcg/actuation” to “17 mcg/actuation”
  o Change “Solution, nebulizing” to “Nebulization Solution, Inhalation”

Salmeterol

S:/MHMR Facilities/Mental Health Facilities/Clinical Services/OMD/Pharmacy EFC/EFC/Interim Update 11-19-14
Delete Aerosol, inhalation: 25 mcg/dose – no longer available

Terbutaline
- Delete trade name “Brethine”
- Delete Aerosol, oral: 0.2 mg/actuation – no longer available
- Remove terbutaline from respiratory section

Theophylline
- Delete all theophylline products. Any current patients on theophylline can obtain medication via the non-formulary process

Tiotropium
- Add Inhaler, aerosol solution Respimat® 1.25 mcg/actuation, 2.5 mcg/actuation

Respiratory Section:

Bronchodilators, Combination/Short Acting
- Albuterol-Ipratropium
  - Delete trade name “DuoNeb” as no longer available
  - Delete Inhaler, oral: Albuterol 103 mcg – Ipratropium 18 mcg
  - Add Combivent Respimat, albuterol 100 mcg – Ipratropium 20 mcg
  - Change “Solution, inhalation” to “Nebulization Solution, inhalation”

Bronchodilators, Combination Steroid + Long Acting Beta-2 Agonists
- Fluticasone – salmeterol
  - Add Aerosol, inhalation; fluticasone 45 mcg – salmeterol 21 mcg; fluticasone 115 mcg – salmeterol 21 mcg; fluticasone 230 mcg – salmeterol 21 mcg

Steroids
- General changes
  - Change this section name to “Inhaled Corticosteroids”
- Beclomethasone
  - Delete trade name “Beconase” as no longer available
- Budesonide
  - Add Powder, inhalation Flexhaler: 90 mcg/actuation; 180 mcg/actuation
  - Change Solution, inhalation to Suspension, inhalation
- Fluticasone
  - Add Powder, inhalation Diskus: 50 mcg/actuation; 100 mcg/actuation; 250 mcg/actuation
- Fluticasone – salmeterol
  - Also listed in the Bronchodilators, Combination Steroid + Long Acting Beta-2 Agonists section
  - Add Aerosol, inhalation; fluticasone 45 mcg – salmeterol 21 mcg; fluticasone 115 mcg – salmeterol 21 mcg; fluticasone 230 mcg – salmeterol 21 mcg
- Mometasone
  - Move to nasal section
- Triamcinolone
  - Delete Aerosol, oral, inhalation: 100 mcg/metered spray as no longer available
  - Move to nasal section
  - Delete size

Miscellaneous Respiratory Drugs
- Acetylcysteine
  - Delete trade name “Mucomyst”
- Cromolyn
  - Delete trade name “Intal”
- Zafirlukast
  - Delete trade name “Accolate”
Cough, Cold and Decongestant Preparations

- **Benzonatate**
  - Delete trade name “Tessalon “Perle”

- **Brompheniramine**
  - Change trade name to “Dimetapp Children’s Cold and Allergy”

- **Brompheniramine – pseudoephedrine**
  - Delete trade name “Bromfed”
  - Delete Capsule; Brompheniramine 12 mg – pseudoephedrine 120 mg as no longer available
  - Delete Elixir: Brompheniramine 4 mg – pseudoephedrine 30 mg as no longer available
  - Delete Liquid: Brompheniramine 12 mg – pseudoephedrine 1 mg per 5 ml as no longer available
  - Delete Syrup: Brompheniramine 2 mg – pseudoephedrine 30 mg as no longer available
  - Delete Tablet, sustained release: Brompheniramine 8 mg – pseudoephedrine 120 mg as no longer available

- **Cetirizine**
  - Add to this section

- **Chlorpheniramine**
  - Delete trade names “Chlor-Trimeton” and “Teldrin”
  - Delete Capsule: 12 mg as no longer available
  - Delete Tablet: 8 mg; 12 mg as no longer available
  - Delete Tablet, chewable: 2 mg as no longer available
  - Delete Tablet, timed release: 8 mg as no longer available

- **Dextromethorphan**
  - List only dosage forms. Consider all strengths for dosage forms listed as being on Formulary
  - Consider any combination of drugs with dextromethorphan as being on Formulary as long as the individual ingredients are on the Formulary and the dosage form is listed as being on Formulary

- **Diphenhydramine**
  - Delete Tablet: 50 mg as no longer available

- **Fexofenadine/Pseudoephedrine**
  - Add Tablet, extended release 24 hr: fexofenadine 180 mg – pseudoephedrine 240 mg

- **Guaifenesin-Codine**
  - Delete trade name “Robitussin AC”

- **Guaifenesin-Dextromethorphan**
  - Delete trade name “Robitussin DM”
  - List only dosage forms. Consider all strengths for dosage forms listed as being on Formulary
  - Consider any combination of drugs with dextromethorphan as being on Formulary as long as the individual ingredients are on the Formulary and the dosage form is listed as being on Formulary

- **Hydrocodone-Guaifenesin**
  - Delete trade names “Hycotuss” and “Kwelcof”
  - Change dosage strength to hydrocodone 2.5 mg-guaifenesin 200 mg per 5 ml

- **Phenylephrine**
  - Move to nasal section
  - Delete Solution, nasal, drops: 0.25%; 0.5%

- **Pseudoephedrine**
  - Change Liquid, oral concentration to 15 mg/5 ml; 30 mg/5 ml
  - Delete tablet, timed release: 120 mg as not available
  - Delete tablet, extended release: 240 mg as not available

- **Triprolidine-Pseudoephedrine**
  - Change trade name to “Aprodine”
  - Delete capsule, extended release: triprolidine 5 mg – pseudoephedrine 120 mg as not available
Delete syrup: triprolidine 1.25 mg – pseudoephedrine 30 mg per 10 ml as not available

**Expectorants**
- Guaifenesin
  - Delete Caplet, sustained release: 600 mg as no longer available
  - Delete Liquid, oral: 200 mg/5 ml as no longer available
  - Delete Tablet: 100 mg as no longer available
- Potassium Iodide
  - Delete Solution, oral: 100 mg/ml as no longer available

**Antihistamines**
- Cetirizine
  - Delete Tablet, chew: 5 mg, 10 mg
- Chlorpheniramine
  - Delete trade names “Chlor-Trimeton” and “Teldrin”
  - Delete Capsule: 12 mg as no longer available
  - Delete Tablet: 8 mg; 12 mg as no longer available
  - Delete Tablet, chewable: 2 mg as no longer available
  - Delete Tablet, timed release: 8 mg as no longer available
- Diphenhydramine
  - Delete Tablet: 50 mg as no longer available
- Hydroxyzine
  - Delete Suspension: 25 mg/5 ml as not available from wholesaler
  - Delete Tablet: 100 mg

Approved:

**Ann Richards, Pharm.D, BCPP**
Ann Richards, Pharm., D., BCPP
Pharmacy Services Director
San Antonio State Hospital